CytoGenix' 2006 - Year in Review.HOUSTON -- CytoGenix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX): During the course of 2006, CytoGenix began the transition from a company of product development to that of sales and marketing. Supporting this transition will require major changes that include a new CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and a top-level management group, expanding the circle of securing strategic partnerships and government grants. 2006 was an excellent year, scientifically. The Company's accomplishments included: * The transition from bacterially-produced plasmid DNA to bacteria-free DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. (synDNA[TM]) * The resumption of completion of tests for Simplivir[TM] (anti-herpes product) * Successful completion of animal testing for a number of DNA vaccines, including HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , smallpox, hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic ., seasonal flu, and brucellosis brucellosis (br  'səlō`sĭs) or Bang's disease, infectious disease of farm animals that is sometimes transmitted to humans. * Commencement of tests on avian flu * Negotiations of a cooperative research and development agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. with a government agency to develop three additional DNA vaccines, including equine encephalitis and ebola * Significant progress in the development of the Company's anti-bacterial compounds against methicillin-resistant staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. and tuberculosis * Generation of revenue from sales of synDNA[TM] to other companies * Construction of a major manufacturing facility to manufacture large-scale synDNA[TM] Despite an excellent year of scientific accomplishments, the stock price has eroded significantly, which is attributable to several reasons: * The announcement of scientific advances did not translate into the immediate, visible sales and profits expected * Restructuring of top-level management * Negative impact on investor relations resulting from above The Company has every intention of improving its investor relations and communications in order to better reflect, not only the value of the science, but also the value of the Company. As the transition progresses, the Company anticipates there will be an increasing volume of exciting information that the Company will be releasing as it becomes reportable. In addition, the Company has engaged Stonebridge Holdings, Inc., an investor relations firm in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , to provide a range of investor-related services. A more comprehensive and detailed summary of our progress in 2006 will be published on www.cytogenix.com. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the Company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion